Microparticles in diabetic kidney disease

Kanakalakshmi, Sushma Thimmaiah; Swaminathan, Shilna Muttickal; Mohan, Pooja Basthi; Nagaraju, Shankar Prasad; Bhojaraja, Mohan V; Laxminarayana, Sindhura Lakshmi Koulmane

doi:10.1016/j.cca.2022.05.001

Cited by 1 publication

(1 citation statement)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current new biomarkers mainly target diagnoses of inflammation, endothelial damage, fibrosis, endothelial dysfunction, and kidney damage, 141 including TNF-α receptor, 142 intercellular adhesion molecule-1, 143 endostatin, 144 copeptin, 145 kidney injury molecule-1, 146 , 147 monocyte chemoattractant protein-1, 148 and neutrophil gelatinase-associated lipocalins. 149 Extracellular vesicles have recently attracted interest, 150 because they are essentially exosomes and particles 151 that transport miRNA, 152 mRNA, 153 , 154 and proteins, 155 and might serve as early biomarkers of DKD. In addition to individual biomarkers, other approaches such as proteomics, 156 genomics, 157 and metabolomics 158 all play roles in screening, especially in studies of chronic kidney disease (CKD) 159 which can predict the development of proteinuria.…”

Section: Introductionmentioning

confidence: 99%

Diabetic vascular diseases: molecular mechanisms and therapeutic strategies

Liu

et al. 2023

Sig Transduct Target Ther

147

View full text Add to dashboard Cite

Vascular complications of diabetes pose a severe threat to human health. Prevention and treatment protocols based on a single vascular complication are no longer suitable for the long-term management of patients with diabetes. Diabetic panvascular disease (DPD) is a clinical syndrome in which vessels of various sizes, including macrovessels and microvessels in the cardiac, cerebral, renal, ophthalmic, and peripheral systems of patients with diabetes, develop atherosclerosis as a common pathology. Pathological manifestations of DPDs usually manifest macrovascular atherosclerosis, as well as microvascular endothelial function impairment, basement membrane thickening, and microthrombosis. Cardiac, cerebral, and peripheral microangiopathy coexist with microangiopathy, while renal and retinal are predominantly microangiopathic. The following associations exist between DPDs: numerous similar molecular mechanisms, and risk-predictive relationships between diseases. Aggressive glycemic control combined with early comprehensive vascular intervention is the key to prevention and treatment. In addition to the widely recommended metformin, glucagon-like peptide-1 agonist, and sodium-glucose cotransporter-2 inhibitors, for the latest molecular mechanisms, aldose reductase inhibitors, peroxisome proliferator-activated receptor-γ agonizts, glucokinases agonizts, mitochondrial energy modulators, etc. are under active development. DPDs are proposed for patients to obtain more systematic clinical care requires a comprehensive diabetes care center focusing on panvascular diseases. This would leverage the advantages of a cross-disciplinary approach to achieve better integration of the pathogenesis and therapeutic evidence. Such a strategy would confer more clinical benefits to patients and promote the comprehensive development of DPD as a discipline.

show abstract